Silexion Therapeutics Corp
SLXNNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $129.91K
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $0.16$20.40
- Volume (live)
- -
- Avg. volume (3M)
- 20.92M
Silexion Therapeutics (SLXN) Stock Price & Financial Analysis
Silexion Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $0.15 - $0.19 |
|---|---|
| 52-Week High | $20.40 |
| 52-Week Low | $0.16 |
| Open | $0.19 |
| Volume (last close) | 832.10K |
| Average Volume (3M) | 20.92M |
| 50-Day MA | $0.46 |
|---|---|
| 200-Day MA | $4.36 |
| 1-Year Change | −94.63% |
| Market Cap | 129.91K |
|---|---|
| Shares Outstanding | 687.35K |
| Price to Book (P/B) | 2.95 |
| EV/EBITDA | 0.05 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Silexion Therapeutics at a Glance
As of the Oct 16, 2026 close, Silexion Therapeutics (SLXN) has a market capitalization of $129.91K.
As of its latest reported balance sheet, it holds $2.23M in cash and securities against $1.41M of debt, a net cash position of $819.00K.
Silexion Therapeutics does not currently pay a dividend.
The share price is down 94.6% over the past year. At $0.15 (the Oct 16, 2026 close) it sits near the bottom of its 52-week range of $0.16 to $20.40, below its 200-day moving average of $4.36.
Frequently Asked Questions About Silexion Therapeutics
What is the current stock price for SLXN?
As of the Oct 16, 2026 close, SLXN stock trades at $0.15. The 52-week range is $0.16–$20.40, with a day range of $0.15–$0.19.
What is the P/E ratio for SLXN?
The P/E ratio (Price-to-Earnings) for SLXN is shown in the Key Statistics section. This valuation metric helps compare Silexion Therapeutics Corp to industry peers.
Does SLXN pay dividends?
Silexion Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for SLXN?
Analyst ratings and recommendations for SLXN are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.
What is the market cap of SLXN?
As of the Oct 16, 2026 close, Silexion Therapeutics's market capitalization is $105,165.009, classifying it as a micro-cap company. Silexion Therapeutics operates in the Healthcare sector within the Biotechnology industry.